The Liver Cirrhosis Treatment Market is expected to reach USD 14803.26 Million by 2030 at 10.90% CAGR during the forecast period 2022-2030
$14803.26 Million
10.90%
North America
2022-2030
The Liver Cirrhosis Treatment Market is expected to reach USD 14803.26 Million by 2030 at 10.90% CAGR during the forecast period 2022-2030
Liver Cirrhosis Treatment Market Synopsis
Liver cirrhosis is a disease in which the liver is severely damaged and scarred, hence leading to liver failure. A lot of research activities are being carried out by major pharmaceutical companies to develop novel drugs for the treatment of liver cirrhosis. Rapidly changing lifestyle is increasing the risk of people suffering from liver cirrhosis. Moreover, people suffering from hepatitis, cystic fibrosis, syphilis, alpha-1 antitrypsin deficiency, alcohol abuse, and other liver diseases are at greater risk of suffering from liver cirrhosis. As of 2015, 887,000 deaths people died suffering from hepatitis B. Most of these deaths were because these patients were suffering from liver cirrhosis and hepatocellular carcinoma (primary liver cancer) along with hepatitis B.
Market Influencer
The increasing prevalence of liver cirrhosis expected to contribute to the growth of the liver cirrhosis treatment market in the near future.
Market Drivers
Market Restraints
Liver Cirrhosis Treatment Market Segmentation
By Treatment
By End-User
By Region
Liver Cirrhosis Treatment Market Key Players
Report Attribute/Metric | Details |
---|---|
Market Size | 2030 : USD 14803.26 Million |
CAGR | 10.90% (2022-2030) |
Base Year | 2021 |
Forecast Period | 2022-2030 |
Historical Data | 2020 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Treatment, End User |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Pfizer, Inc. (US), Merck & Co., Inc. (Germany), Novartis AG (Switzerland), Hoffmann-La Roche Ltd (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Gilead Sciences, Inc. (US), AstraZeneca (UK), Bayer AG (Germany), Sanofi (France), Shionogi Inc. (Japan), Promethera (Belgium) |
Key Market Opportunities | New product launches and R&D Amongst major key Players |
Key Market Drivers |
|
The liver cirrhosis treatment was valued at USD 14803.26 Million in 2030.
The liver cirrhosis treatment is expected to exhibit a strong 10.90% CAGR over the forecast period from 2022 to 2030.
Growing prevalence of alcoholism is likely to be a major driver for the liver cirrhosis treatment.
The Americas are the largest regional market for liver cirrhosis treatment.
Leading players in the market include Merck, Novartis, and Pfizer, among others.